Shares of Allena Pharmaceuticals Inc (NASDAQ:ALNA) have been given a consensus rating of “Buy” by the eight brokerages that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $25.20.

A number of analysts recently commented on the company. Cowen reiterated a “buy” rating on shares of Allena Pharmaceuticals in a research report on Friday, May 10th. Zacks Investment Research cut Allena Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. Wedbush reiterated a “buy” rating and set a $39.00 price objective on shares of Allena Pharmaceuticals in a research report on Sunday, March 10th. B. Riley set a $22.00 price objective on Allena Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, March 8th. Finally, Robert W. Baird initiated coverage on Allena Pharmaceuticals in a research report on Friday, January 18th. They set an “outperform” rating and a $20.00 price objective for the company.

Allena Pharmaceuticals stock traded down $0.37 during mid-day trading on Friday, reaching $5.25. 134,706 shares of the stock traded hands, compared to its average volume of 41,480. The stock has a market cap of $119.28 million, a PE ratio of -3.05 and a beta of 1.69. The company has a debt-to-equity ratio of 0.24, a quick ratio of 11.19 and a current ratio of 7.83. Allena Pharmaceuticals has a 12-month low of $4.80 and a 12-month high of $16.61.

Allena Pharmaceuticals (NASDAQ:ALNA) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). As a group, sell-side analysts predict that Allena Pharmaceuticals will post -1.95 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers purchased a new stake in Allena Pharmaceuticals in the fourth quarter worth about $78,000. Renaissance Technologies LLC purchased a new stake in Allena Pharmaceuticals in the first quarter worth about $104,000. State of Wisconsin Investment Board increased its position in Allena Pharmaceuticals by 30.0% in the first quarter. State of Wisconsin Investment Board now owns 15,600 shares of the company’s stock worth $110,000 after buying an additional 3,600 shares in the last quarter. Wells Fargo & Company MN increased its position in Allena Pharmaceuticals by 51.9% in the first quarter. Wells Fargo & Company MN now owns 21,311 shares of the company’s stock worth $150,000 after buying an additional 7,283 shares in the last quarter. Finally, Deutsche Bank AG increased its position in Allena Pharmaceuticals by 8.2% in the fourth quarter. Deutsche Bank AG now owns 28,023 shares of the company’s stock worth $151,000 after buying an additional 2,118 shares in the last quarter. Institutional investors and hedge funds own 80.00% of the company’s stock.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

See Also: Do Tariffs Work?

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.